FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Palmedo Philip F		 2. Issuer Name and Ticker or Trading Symbol

LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

680 E. COLORADO BLVD., SUITE 180		 3. Date of Earliest Transaction (MM/DD/YYYY)

6/30/2022
(Street)

PASADENA, CA 91101
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Options to Purchase Common Stock $0.7446 6/30/2022  A   100000    6/30/2022 6/30/2027 Common 100000 $0 (1)100000 D  
Options to Purchase Common Stock $3.03           6/30/2021 6/30/2026 Common 100000  100000 D  
Options to Purchase Common Stock $3.21           1/6/2021 1/6/2026 Common 50000  50000 D  
Warrants to Purchase Common Stock $5.70           11/30/2020 11/30/2025 Common 21053  21053 D  
Options to Purchase Common Stock $0.72           4/25/2016 4/25/2021 Common 75000  75000 D  
Warrants to Purchase Common Stock $6.00           12/7/2018 12/7/2022 Common 16667  16667 I By Philip Palmedo L.P.. 
Options to Purchase Common Stock $0.90           10/16/2017 10/16/2022 Common 8333  8333 D  
Options to Purchase Common Stock $6.60           5/22/2019 5/22/2024 Common 8333  8333 D  
Explanation of Responses:
(1) Effective June 30, 2022, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2022).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Palmedo Philip F
680 E. COLORADO BLVD., SUITE 180
PASADENA, CA 91101		X
Signatures
/s/ Philip Palmedo7/1/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Lixte Biotechnology Charts.
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Lixte Biotechnology Charts.